Payment overview · 2025
General Payments
$1,238.86
75 reported records · 24 companies
Healthcare provider profile · identity verified
David James Sandercock, DO
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1871672436
Verified facts
What the public records show
CMS Open Payments records show David James Sandercock, DO received $1,238.86 in general payments during 2025 across 75 reported records.
PFIZER INC. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $256.03 | 20.7% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $228.27 | 18.4% | 14 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $138.71 | 11.2% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $68.63 | 5.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.58 | 5.3% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.25 | 4.9% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $46.64 | 3.8% | 2 | 2025 |
| ALK-Abello, Inc | Unresolved — no canonical attribution shown | $35.12 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.21 | 2.8% | 2 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $32.19 | 2.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $29.55 | 2.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $23.10 | 1.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.84 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.54 | 1.8% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.49 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.43 | 1.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.39 | 1.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.22 | 1.5% | 1 | 2025 |
| RGH Enterprises LLC | Unresolved — no canonical attribution shown | $18.00 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.99 | 1.3% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $15.41 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.36 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.06 | 1.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.85 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,238.86 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $172.01 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $168.81 | 13 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $115.04 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $90.65 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.58 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.58 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $61.68 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.25 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.26 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $49.64 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.64 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.06 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $46.64 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $44.33 | 5 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $44.25 | 3 | 2025 |
Source payment records
|
|||||
| Grastek Normalized: grastek |
Drug | ALK-Abello, Inc | $35.12 | 1 | 2025 |
Source payment records
|
|||||
| Odactra Normalized: odactra |
Drug | ALK-Abello, Inc | $35.12 | 1 | 2025 |
Source payment records
|
|||||
| Ragwitek Normalized: ragwitek |
Drug | ALK-Abello, Inc | $35.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $32.19 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $29.55 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.21 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $23.10 | 2 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $22.84 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.54 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.49 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $18.99 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.99 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $15.41 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 14 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 417 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 393 | 108 |
| Losartan Potassium | Losartan Potassium | 334 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 320 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 297 | 87 |
| Lisinopril | Lisinopril | 250 | 72 |
| Simvastatin | Simvastatin | 217 | 62 |
| Gabapentin | Gabapentin | 213 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 56 |
| Alprazolam | Alprazolam | 199 | 39 |
| Metformin Hcl Er | Metformin Hcl | 180 | 49 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 46 |
| Omeprazole | Omeprazole | 174 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 161 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 34 |
| Meloxicam | Meloxicam | 137 | 37 |
| Trazodone Hcl | Trazodone Hcl | 121 | 33 |
| Montelukast Sodium | Montelukast Sodium | 114 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 108 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 106 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 105 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 105 | 32 |
| Tramadol Hcl | Tramadol Hcl | 105 | 29 |
| Glimepiride | Glimepiride | 103 | 32 |
| Furosemide | Furosemide | 102 | 33 |
| Bupropion Xl | Bupropion Hcl | 94 | 21 |
| Sertraline Hcl | Sertraline Hcl | 91 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 20 |
| Azithromycin | Azithromycin | 89 | 71 |
| Farxiga | Dapagliflozin Propanediol | 87 | 24 |
| Metformin Hcl | Metformin Hcl | 86 | 28 |
| Buspirone Hcl | Buspirone Hcl | 83 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 80 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 27 |
| Clonazepam | Clonazepam | 78 | 17 |
| Allopurinol | Allopurinol | 77 | 27 |
| Ozempic | Semaglutide | 68 | 19 |
| Potassium Chloride | Potassium Chloride | 66 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 17 |
| Ezetimibe | Ezetimibe | 64 | 16 |
| Carvedilol | Carvedilol | 63 | 20 |
| Famotidine | Famotidine | 59 | 22 |
| Jardiance | Empagliflozin | 56 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 50 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | 15 |
| Atenolol | Atenolol | 48 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 48 | 16 |
| Alendronate Sodium | Alendronate Sodium | 46 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 45 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 44 | suppressed |
| Spironolactone | Spironolactone | 44 | 14 |
| Ibuprofen | Ibuprofen | 43 | 18 |
| Januvia | Sitagliptin Phosphate | 43 | 11 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Synthroid | Levothyroxine Sodium | 42 | 12 |
| Valacyclovir | Valacyclovir Hcl | 42 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 41 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | 14 |
| Temazepam | Temazepam | 40 | suppressed |
| Eliquis | Apixaban | 39 | suppressed |
| Irbesartan | Irbesartan | 39 | 12 |
| Azelastine Hcl | Azelastine Hcl | 35 | 14 |
| Finasteride | Finasteride | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 12 |
| Lorazepam | Lorazepam | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Naproxen | Naproxen | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 14 |
| Amoxicillin | Amoxicillin | 26 | 18 |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Prednisone | Prednisone | 25 | 14 |
| Pregabalin | Pregabalin | 25 | suppressed |
| Verapamil Er | Verapamil Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 13 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 13 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Indapamide | Indapamide | 19 | suppressed |
| Telmisartan | Telmisartan | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Jantoven | Warfarin Sodium | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Ramelteon | Ramelteon | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 11 |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,238.86 · 75 records | PFIZER INC. | AJOVY, AREXVY, Azstarys, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, Fluad, Flucelvax, GARDASIL 9, GVOKE HYPOPEN, Grastek, Heplisav-B, KRYSTEXXA, Kerendia, Korlym, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Odactra, Ozempic, PAXLOVID, QULIPTA, REPATHA, Ragwitek, Rybelsus, SHINGRIX, Symbravo, TZIELD, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error